Evidence-Based Risk Factors for Seroma Formation in Breast Surgery, Japanese Journal of Clinical Oncology, vol.36, issue.4, pp.197-206, 2006. ,
DOI : 10.1093/jjco/hyl019
The Use of Closed Suction Drainage After Lumpectomy and Axillary Node Dissection for Breast Cancer A Prospective Randomized Trial, Annals of Surgery, vol.215, issue.2, pp.146-149, 1992. ,
DOI : 10.1097/00000658-199202000-00009
Randomized clinical trial comparing axillary padding with closed suction drainage for the axillary wound after lymphadenectomy for breast cancer, British Journal of Surgery, vol.89, issue.7, pp.820-824, 2006. ,
DOI : 10.1002/bjs.5433
Sealants after axillary lymph node dissection for breast cancer: good intentions but bad results, The American Journal of Surgery, vol.198, issue.1, pp.55-58, 2009. ,
DOI : 10.1016/j.amjsurg.2008.06.043
External compression dressing versus standard dressing after axillary lymphadenectomy, Am J Surg, vol.177, pp.450-453, 1999. ,
Delayed versus immediate exercises following surgery for breast cancer: a systematic review, Breast Cancer Research and Treatment, vol.82, issue.3, pp.263-271, 2005. ,
DOI : 10.1007/s10549-004-4727-9
Electrocautery as a factor in seroma formation following mastectomy, The American Journal of Surgery, vol.176, issue.1, pp.8-11, 1998. ,
DOI : 10.1016/S0002-9610(98)00093-2
Prevention of seroma formation after axillary dissection in breast cancer: A systematic review, European Journal of Surgical Oncology (EJSO), vol.37, issue.10, pp.829-835, 2011. ,
DOI : 10.1016/j.ejso.2011.04.012
URL : https://hal.archives-ouvertes.fr/hal-00732664
Octreotide in the treatment of refractory diarrhoea and intestinal fistulae., Gut, vol.35, issue.3 Suppl, pp.5-10, 1994. ,
DOI : 10.1136/gut.35.3_Suppl.S5
Octreotide in the treatment of lymphorrhea after axillary node dissection: a prospective randomized controlled trial, Journal of the American College of Surgeons, vol.196, issue.3, pp.365-374, 2003. ,
DOI : 10.1016/S1072-7515(02)01757-X
Octreotide Can Control Lymphorrhea after Axillary Node Dissection in Mastectomy Operations, The Breast Journal, vol.73, issue.1, pp.108-117, 2007. ,
DOI : 10.1016/0026-0495(90)90241-4
Lanreotide autogel 90??mg and lymphorrhea prevention after axillary node dissection in breast cancer: A phase III double blind, randomized, placebo-controlled trial, European Journal of Surgical Oncology (EJSO), vol.38, issue.10, pp.902-911, 2012. ,
DOI : 10.1016/j.ejso.2012.05.009
A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease, New England Journal of Medicine, vol.366, issue.10, pp.914-938, 2012. ,
DOI : 10.1056/NEJMoa1105743
SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile, European Journal of Endocrinology, vol.146, issue.5, pp.707-716, 2002. ,
DOI : 10.1530/eje.0.1460707
Randomized Phase II Trials: Time for a New Era in Clinical Trial Design, Journal of Thoracic Oncology, vol.5, issue.7, pp.932-924, 2010. ,
DOI : 10.1097/JTO.0b013e3181e2eadf
Bayesian sample size calculations for a non-inferiority test of two proportions in clinical trials, Contemporary Clinical Trials, vol.29, issue.4, pp.507-516, 2008. ,
DOI : 10.1016/j.cct.2007.12.001
Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: A tutorial, Contemporary Clinical Trials, vol.29, issue.4, pp.608-616, 2008. ,
DOI : 10.1016/j.cct.2007.11.005
Future medical prospects for Sandostatin, Metabolism, vol.39, issue.9, pp.180-185, 1990. ,
DOI : 10.1016/0026-0495(90)90241-4
Somatostatin in breast cancer, Ann Biol Clin, vol.69, pp.385-391, 2011. ,
Reduction of lymphorrhagia from ruptured thoracic duct by somatostatin, The Lancet, vol.336, issue.8709, p.258, 1990. ,
DOI : 10.1016/0140-6736(90)91793-A
Functional Activity of the Multiligand Analog SOM230 at Human Recombinant Somatostatin Receptor Subtypes Supports Its Usefulness in Neuroendocrine Tumors, Neuroendocrinology, vol.80, issue.1, pp.47-50, 2004. ,
DOI : 10.1159/000080741
Octreotide in the Treatment of Lymphorrhea After Renal Transplantation: A Preliminary Experience, Transplantation Proceedings, vol.38, issue.4, pp.1047-1048, 2006. ,
DOI : 10.1016/j.transproceed.2006.03.040
Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study, Cancer Chemotherapy and Pharmacology, vol.29, issue.Suppl 1, pp.387-395, 2013. ,
DOI : 10.1007/s00280-013-2202-1